Who Paid My Doc
Forxiga HF-D1699C00001 HF rEF Outcome study
Research payments
$3,690,749
Through program year 2024, $3,690,749 in research payments was reported against Forxiga HF-D1699C00001 HF rEF Outcome study, across 319 payments.
- Paid by (largest first)
- AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $13,305 | 1 |
| 2022 | Research | $1,242,236 | 4 |
| 2020 | Research | $104,713 | 58 |
| 2019 | Research | $2,330,494 | 256 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Joseph Izzo Buffalo, NY Named on 16 payments
- Cezar Staniloae New York, NY Named on 14 payments
- William French Torrance, CA Named on 12 payments
- Thomas Cimato Buffalo, NY Named on 8 payments
- John Kostis New Brunswick, NJ Named on 8 payments
- Sitaramesh Emani Columbus, OH Named on 8 payments
- Erich Fruehling Grand Island, NE Named on 6 payments
- Denes Korpas Lincoln, NE Named on 6 payments
- James Watts Fort Stewart, GA Named on 6 payments
- Barry Bertolet Tupelo, MS Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.